1. Management of refractory early-stage cutaneous T-cell lymphoma (mycosis fungoides) with a combination of oral bexarotene and psoralen plus ultraviolet bath therapy 
Margit A Huber, MD, Karin Kunzi-Rapp, MD, PhD, Gyde Staib, MD, Karin Scharffetter-Kochanek, MD 
Journal of the American Academy of Dermatology 
Volume 50, Issue 3, Pages (March 2004)
DOI: /S (03)

2. Fig 1
Representative cutaneous lesions in flexural fossae of the lower extremities during combination therapy with oral bexarotene and PUVA bath therapy in a patient with mycosis fungoides. Six weeks after initiation of therapy there is marked improvement of lesions on the left leg, which received additional PUVA irradiation, whereas cutaneous T-cell lymphoma lesions on the right lower extremity (not treated with UV therapy) manifest as partly elevated erythematous plaques.
Journal of the American Academy of Dermatology  , DOI: ( /S (03) )

3. Fig 2
Cutaneous T-cell lymphoma (CTCL) lesions in Fig 1 at week 16 from start of therapy. Progressive improvement is evident. Psoralen plus ultraviolet A therapy of the entire body surface has been performed for 4 weeks. Complete clearance of representative CTCL lesions on the left leg is evident, as is significant clearance on the right leg.
Journal of the American Academy of Dermatology  , DOI: ( /S (03) )